Abstract 5865
Background
The 21-gene Breast Recurrence Score® (RS) is an established genomic tool to assess recurrence risk and adjuvant chemotherapy benefit in early breast cancer. The TAILORx study redefined group boundaries of the RS in node negative women. In the 668 patients of the NSABP-B14 study that formed the validation set of the RS younger age was significantly correlated with distant recurrence and tumour size trended toward significance. High tumour grade remained an independent prognostic factor beyond the RS. In the TAILORx study these higher risk groups were under-represented.
Methods
We compared clinical prognostic parameters of women in South East London with available RS with the TAILORx trial population. Retrospective case note analysis of all identified patients between 2013 and 2018 was completed. Women with nodal involvement were excluded. Descriptive statistics were used for comparison with patient characteristics of the TAILORx study.
Results
A total of 269 tests were identified. 42 were excluded for nodal involvement or incomplete clinical data, leaving 227 patients. Differences between the populations are demonstrated for all characteristics and will be presented at the meeting.Table:
263P Patient characteristic
RS | <11 | 11-25 | >26 | ALL |
N (%) | 34 (11) | 142 (67) | 51 (22) | 227 (100) |
Median age (range) | 48 (28-75) | 49 (28-74) | 53 (38-78) | 50 (28-78) |
≤50 yr % | 56 | 56 | 41 | 52 |
Premenopausal % | 59 | 64 | 47 | 59 |
Tumour size in cm Median (IQR) Mean (SD) | 2.0 (1.7-3.0) 2.6 ± 1.5 | 2.1 (1.5-3.0) 2.6 ± 1.8 | 2.2 (1.6-3.0) 2.4 ± 1.2 | 2.1 (1.6-3.0) 2.6 ± 1.6 |
Tumour grade % Low Intermediate High | 6 74 21 | 4 63 33 | 0 24 76 | 4 56 41 |
Clinical risk % Low High High (TAILORx) | 35 65 22 | 32 68 26 | 20 80 57 | 30 70 |
Conclusions
Our patients have a higher clinical risk than the TAILORx population. They are younger and have larger, higher grade cancers. This population is under-represented in the TAILORx study which was unable to exclude benefit in the ≤ 50 subset and may thus underestimate benefit from chemotherapy in our population. The current RS reporting is biased towards an older, low-risk population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Gousis: Travel / Accommodation / Expenses: Roche. H. Kristeleit: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Advisory / Consultancy: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Presenter: Alberto Ocaña
Session: Poster Display session 2
Resources:
Abstract
1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
Presenter: Jianfei Fu
Session: Poster Display session 2
Resources:
Abstract
1978 - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators
Presenter: Fanrong Zhang
Session: Poster Display session 2
Resources:
Abstract
3062 - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
Presenter: Sujin Yang
Session: Poster Display session 2
Resources:
Abstract
5274 - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers
Presenter: Gayathri Devi
Session: Poster Display session 2
Resources:
Abstract
1324 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients
Presenter: Soo Youn Bae
Session: Poster Display session 2
Resources:
Abstract
4877 - Correlation of clinical and pathological features with the tumour microenvironment in DCIS. An institutional experience
Presenter: Ann Eapen
Session: Poster Display session 2
Resources:
Abstract
2471 - Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Presenter: Ariadna Gasol Cudos
Session: Poster Display session 2
Resources:
Abstract
2632 - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Presenter: Norio Masumoto
Session: Poster Display session 2
Resources:
Abstract
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract